Market Overview:
The global opioid induced constipation (OIC) drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic pain, rising awareness about OIC drugs, and the launch of new products. The global opioid induced constipation (OIC) drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into lubiprostone, methyl naltrexone bromide, naldemedine alvimopan and other products. Lubiprostone held a major share in 2017 owing to its high efficacy and safety profile. On the basis of application, hospital pharmacies accounted for a major share in 2017 as these pharmacies stock up on OIC drugs for patients suffering from chronic pain conditions.
 Drugs Industry Outlook.svg)
Product Definition:
Opioid Induced Constipation (OIC) Drugs are those which are used to relieve constipation caused by opioid pain medications.
Lubiprostone:
Lubiprostone is a lubiprofen-4-carboxylate salt. Lubiprostone works by blocking the release of prostaglandins, which causes diarrhea in patients who are taking it for pain management or to prevent diarrhea. It also reduces the amount of fluid secreted from the stomach and intestine through contraction, thus treating OICD (Optic Neuropathy with Diarrhea).
Methyl Naltrexone Bromide:
Methyl naltrexone bromide is an opioid antagonist used in the treatment of diarrhea associated with opioid addiction. It is also used as a second-line of treatment for OIC and can be combined with mesalamine (PMA) or 5-ASA as a fixed dose combination product under the brand name “Jornay”.
Application Insights:
Based on the application, the global market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The online pharmacy segment held a significant share of over 40% in 2017 owing to its convenience and accessibility. Patients can order medicines through websites or mobile applications without visiting a pharmacy. However, this may increase the risk of drug abuse since it is easier for patients to get hold of drugs from internet sources than from medical stores.
The hospital pharmacy segment held a larger share due to high usage rates of opioid induced constipation (OIC) drugs in hospitals as compared to other places such as clinics and homes.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to witness a growth rate of 5.6% over the forecast period, owing to rising cases of opioid-related disorders and awareness about OIC drugs among patients suffering from constipation due to opioids. In addition, high adoption of OTC laxatives by patients in this region further drives the demand for effective and safer alternatives for opioid-induced constipation treatment.
Asia Pacific is expected to be one of fastest growing regions during the forecast period owing to increasing cases of chronic pain coupled with rapidly developing healthcare infrastructure in emerging countries such as China.
Growth Factors:
- Increasing incidence of OIC due to increasing number of opioid prescriptions
- Growing awareness about the availability and efficacy of OIC drugs
- Launch of novel drugs with better efficacy and safety profile
- Rising demand for effective treatments for chronic constipation
- Entry of new players in the market
Scope Of The Report
Report Attributes
Report Details
Report Title
Opioid Induced Constipation (OIC) Drugs Market Research Report
By Type
Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Pfizer, Progenics Pharmaceuticals Inc, Shionogi & Co., Ltd, Allergan Plc, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma AG, Mundipharma International Limited, Ono Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited, Theravance Biopharma Inc, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Opioid Induced Constipation (OIC) Drugs Market Report Segments:
The global Opioid Induced Constipation (OIC) Drugs market is segmented on the basis of:
Types
Lubiprostone, Methyl Naltrexone Bromide, Naldemedine, Alvimopan, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ironwood Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Pfizer
- Progenics Pharmaceuticals Inc
- Shionogi & Co., Ltd
- Allergan Plc
- Nektar Therapeutics
- Purdue Pharma
- S.L.A. Pharma AG
- Mundipharma International Limited
- Ono Pharmaceutical Co., Ltd
- Takeda Pharmaceutical Company Limited
- Theravance Biopharma Inc
- Valeant Pharmaceuticals International
- Cosmo Pharmaceuticals SA
- Daewoong Pharmaceutical
- C.B. Fleet Company
- Sucampo Pharmaceuticals
 Drugs Market Overview.svg)
Highlights of The Opioid Induced Constipation (OIC) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lubiprostone
- Methyl Naltrexone Bromide
- Naldemedine
- Alvimopan
- Other
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Opioid Induced Constipation (OIC) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drugs Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Opioid induced constipation (OIC) drugs are medications that can cause constipation. These drugs include opioids, such as morphine and codeine, and non-opioid pain relievers, such as ibuprofen. OIC can occur when the drug is taken in high doses or for a long period of time.
Some of the key players operating in the opioid induced constipation (oic) drugs market are Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Pfizer, Progenics Pharmaceuticals Inc, Shionogi & Co., Ltd, Allergan Plc, Nektar Therapeutics, Purdue Pharma, S.L.A. Pharma AG, Mundipharma International Limited, Ono Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited, Theravance Biopharma Inc, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, C.B. Fleet Company, Sucampo Pharmaceuticals.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Opioid Induced Constipation (OIC) Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Opioid Induced Constipation (OIC) Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Opioid Induced Constipation (OIC) Drugs Market - Supply Chain
4.5. Global Opioid Induced Constipation (OIC) Drugs Market Forecast
4.5.1. Opioid Induced Constipation (OIC) Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Opioid Induced Constipation (OIC) Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Opioid Induced Constipation (OIC) Drugs Market Absolute $ Opportunity
5. Global Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Type
5.3.1. Lubiprostone
5.3.2. Methyl Naltrexone Bromide
5.3.3. Naldemedine
5.3.4. Alvimopan
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Opioid Induced Constipation (OIC) Drugs Demand Share Forecast, 2019-2026
9. North America Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Type
9.7.1. Lubiprostone
9.7.2. Methyl Naltrexone Bromide
9.7.3. Naldemedine
9.7.4. Alvimopan
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Opioid Induced Constipation (OIC) Drugs Demand Share Forecast, 2019-2026
10. Latin America Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Type
10.7.1. Lubiprostone
10.7.2. Methyl Naltrexone Bromide
10.7.3. Naldemedine
10.7.4. Alvimopan
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Opioid Induced Constipation (OIC) Drugs Demand Share Forecast, 2019-2026
11. Europe Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Type
11.7.1. Lubiprostone
11.7.2. Methyl Naltrexone Bromide
11.7.3. Naldemedine
11.7.4. Alvimopan
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Opioid Induced Constipation (OIC) Drugs Demand Share, 2019-2026
12. Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Type
12.7.1. Lubiprostone
12.7.2. Methyl Naltrexone Bromide
12.7.3. Naldemedine
12.7.4. Alvimopan
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Opioid Induced Constipation (OIC) Drugs Demand Share, 2019-2026
13. Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Opioid Induced Constipation (OIC) Drugs Market Size and Volume Forecast by Type
13.7.1. Lubiprostone
13.7.2. Methyl Naltrexone Bromide
13.7.3. Naldemedine
13.7.4. Alvimopan
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Opioid Induced Constipation (OIC) Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Opioid Induced Constipation (OIC) Drugs Market: Market Share Analysis
14.2. Opioid Induced Constipation (OIC) Drugs Distributors and Customers
14.3. Opioid Induced Constipation (OIC) Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Ironwood Pharmaceuticals Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Daiichi Sankyo Co Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Progenics Pharmaceuticals Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Shionogi & Co., Ltd
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Allergan Plc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Nektar Therapeutics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Purdue Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. S.L.A. Pharma AG
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mundipharma International Limited
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Ono Pharmaceutical Co., Ltd
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Takeda Pharmaceutical Company Limited
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Theravance Biopharma Inc
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Valeant Pharmaceuticals International
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Cosmo Pharmaceuticals SA
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Daewoong Pharmaceutical
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. C.B. Fleet Company
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Sucampo Pharmaceuticals
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
